Observational studyVox sanguinis2026
Use and availability of anti-RhD immunoglobulin in Colombia following the 2024 national shortage.
Observational study in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Use and availability of anti-RhD immunoglobulin in Colombia following the 2024 national shortage.Vox sanguinis · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesIn March 2024, the Colombian National Food and Drug Surveillance Institute declared a shortage of anti-RhD immunoglobulin, a critical product for preventing haemolytic disease of the foetus and newborn (HDFN) in RhD-negative women carrying RhD-positive foetuses. The aim of this work was to analyse the impact of this shortage on obstetric institutions, transfusion services and prophylactic management of the RhD-negative pregnant population. MATERIALS AND
methodsA descriptive, cross-sectional study was conducted using an online survey distributed between December 2024 and February 2025. Data were analysed according to region and experience with shortages.
resultsTwenty-seven institutions (17.9%) providing obstetric and transfusion services completed the survey. Most respondents (88.9%) represented obstetric services, followed by transfusion medicine (7.4%) and clinical pharmacy (3.7%). In 92.6% of institutions, physicians prescribed anti-RhD immunoglobulin. Shortages were reported by 22.2% (n = 6) of institutions. Prophylaxis was administered during weeks 28-40 in 51.9% (n = 14) and during weeks 14-27 in 22.2% (n = 6), while one reported both periods. Anti-D administration was reported postpartum in 44.4% of cases, following abortion in 29.6%, after foetal haemorrhage in 7.4%, after trauma in 3.7% and once at the physician's discretion.
conclusionAlthough some institutions reported shortages of anti-RhD immunoglobulin (particularly in the Andine region), these did not lead to changes in clinical indications, and prophylactic use during late pregnancy and the postpartum period remains the predominant practice nationwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.